ArticleESMO real world data and digital oncology2026
Evolving phase I oncology trials in the precision medicine era: design, outcomes, and geographic access.
Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Over the past decade, early phase oncology trials have evolved from safety-focused designs to precision-oriented strategies. This study evaluated longitudinal trends, focusing on clinical outcomes, trial design evolution, and the impact of comprehensive genomic profiling (CGP) following its national insurance coverage in Japan in 2019. Methods: This retrospective observational study included patients enrolled in early phase oncology trials at National Cancer Center Hospital (NCCH) between 2016 and 2023. Clinical, molecular, and geographic data were extracted from medical records. Categorical outcomes were compared using chi-square tests. Variables were compared between the early period (2016-2019) and the recent period (2020-2023). Results: Over 8 years, 1243 patients were enrolled across 1642 early phase trials. The proportion of patients enrolled in genomically matched trials increased significantly from 10.5% in the early period to 28.4% in the recent period ( Conclusions: The evolving early phase oncology trials, characterized by increased adoption of genomically matched trial designs, broader access to CGP under universal health coverage, and expanded nationwide referral networks, highlight a shift toward more precision in early drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.